M.D. Anderson Cancer Center: Leukemia trials

The registry lists 302 Leukemia studies with M.D. Anderson Cancer Center as lead sponsor. 5 are open to participants now and 169 have results posted.

Early Phase 1 1Phase 1 121Phase 2 201Phase 3 13No phase 26(a study in two phases counts in both)

Studies

Page 1 of 4. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX GenesRecruitingNCT06229912Phase 2
• Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic LeukemiaRecruitingNCT05645718Phase 2
• Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)RecruitingNCT05536349Phase 2
• Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic MalignanciesRecruitingNCT05011045
• Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)RecruitingNCT01515527Phase 2
• Phase II Study to Evaluate Safety and Efficacy of CB-103 With Venetoclax in Adolescent and Young Adult Patients With Relapsed/Refractory T-ALL or T-LBLTerminatedNCT05464836Phase 2Results posted
• DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic LeukemiaTerminatedNCT04752163Phase 1/2Results posted
• Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic SyndromeCompletedNCT04487106Phase 2Results posted
• 2018-0674 - IL-7 for T-Cell Recovery Post Haplo and CB Transplant - Phase I/IICompletedNCT03941769Phase 1/2Results posted
• Venetoclax and Quizartinib in Treating Patients With FLT3-mutated Recurrent or Refractory Acute Myeloid LeukemiaTerminatedNCT03735875Phase 1/2Results posted
• Milademetan Tosylate and Low-Dose Cytarabine With or Without Venetoclax in Treating Participants With Recurrent or Refractory Acute Myeloid LeukemiaTerminatedNCT03634228Phase 1/2Results posted
• Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous LeukemiaTerminatedNCT03576547Phase 1/2Results posted
• Low-Intensity Chemotherapy and Blinatumomab in Treating Patients With Philadelphia Chromosome Negative Relapsed or Refractory Acute Lymphoblastic LeukemiaTerminatedNCT03518112Phase 2Results posted
• OX40, Venetoclax, Avelumab, Glasdegib, Gemtuzumab Ozogamicin, and Azacitidine in Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT03390296Phase 1/2Results posted
• Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or LymphomaCompletedNCT03096782Phase 2Results posted
• Inotuzumab Ozogamicin in Treating Patients With Relapsed or Refractory CD22 Positive Acute Lymphoblastic LeukemiaTerminatedNCT03094611Phase 2Results posted
• Daratumumab in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeTerminatedNCT03067571Phase 2Results posted
• Umbilical & Cord Blood (CB) Derived CAR-Engineered NK Cells for B Lymphoid MalignanciesCompletedNCT03056339Phase 1/2Results posted
• Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic SyndromeCompletedNCT03047993Phase 1/2Results posted
• Ruxolitinib Phosphate in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaCompletedNCT03041636Phase 2Results posted
• Isavuconazole in Preventing Invasive Fungal Infections in Adult Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome and NeutropeniaCompletedNCT03019939Phase 2Results posted
• Avelumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid LeukemiaTerminatedNCT02953561Phase 1/2Results posted
• Bosutinib in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase After Frontline TKI FailureTerminatedNCT02906696Phase 2Results posted
• Oxidative Phosphorylation Inhibitor IACS-010759 in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaTerminatedNCT02882321Phase 1Results posted
• Blinatumomab Maintenance Following Allogeneic Hematopoietic Cell Transplantation for Patients With Acute Lymphoblastic LeukemiaCompletedNCT02807883Phase 2Results posted
• A Study of Different Doses of Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)CompletedNCT02801578Phase 2/3Results posted
• Nivolumab in AML in Remission at High Risk for RelapseCompletedNCT02532231Phase 2Results posted
• Ex Vivo-activated Autologous Lymph Node Lymphocytes in Treating Patients With Chronic Lymphocytic LeukemiaCompletedNCT02530515Phase 2Results posted
• Phase I/II, Study of Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) + Sorafenib in Acute Myeloid LeukemiaCompletedNCT02530476Phase 1/2Results posted
• Lirilumab With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) PatientsCompletedNCT02481297Phase 2Results posted
• Study of Idarubicin, Cytarabine, and Nivolumab in Patients With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)CompletedNCT02464657Phase 1/2Results posted
• Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML)CompletedNCT02441803Phase 2Results posted
• Nivolumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or High-Risk Untreated Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Richter TransformationCompletedNCT02420912Phase 2Results posted
• An Open-label Phase II Study of Lorvotuzumab MertansineCompletedNCT02420873Phase 2Results posted
• Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic LeukemiaTerminatedNCT02420717Phase 2Results posted
• Augmented Berlin-Frankfurt-Munster Therapy Plus Ofatumumab for Young Adults With Acute Lymphoblastic Leukemia or Lymphoblastic LymphomaTerminatedNCT02419469Phase 2Results posted
• Lirilumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid LeukemiaTerminatedNCT02399917Phase 2Results posted
• Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid LeukemiaCompletedNCT02397720Phase 2Results posted
• Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and CMLCompletedNCT02311998Phase 1/2Results posted
• Study of MLN9708 as Maintenance Therapy for Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS) in RemissionTerminatedNCT02302846Phase 2Results posted
• Phase II Decitabine (DAC) Versus Azacitidine (AZA) in Myelodysplastic Syndrome (MDS)CompletedNCT02269280Phase 2Results posted
• Ruxolitinib Phosphate and Decitabine in Treating Patients With Relapsed or Refractory or Post Myeloproliferative Acute Myeloid LeukemiaCompletedNCT02257138Phase 1/2Results posted
• Lenalidomide and Obinutuzumab in Treating Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaTerminatedNCT02225275Phase 2Results posted
• Dose Adjusted EPOCH Regimen in Combination With Ofatumumab or Rituximab in Treating Patients With Newly Diagnosed or Relapsed or Refractory Burkitt Lymphoma or Relapsed or Refractory Acute Lymphoblastic LeukemiaCompletedNCT02199184Phase 2Results posted
• Sorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MS) With FLT3-ITD MutationCompletedNCT02196857Phase 2Results posted
• Clofarabine, Idarubicin, Cytarabine, Vincristine Sulfate, and Dexamethasone in Treating Patients With Newly Diagnosed or Relapsed Mixed Phenotype Acute LeukemiaCompletedNCT02135874Phase 2Results posted
• Lenalidomide in Treating Patients With High Risk Acute Myeloid Leukemia in RemissionCompletedNCT02126553Phase 2Results posted
• Guadecitabine With or Without Idarubicin or Cladribine in Treating Older Patients With Previously Untreated Acute Myeloid LeukemiaCompletedNCT02096055Phase 2Results posted
• Phase I/II - Brentuximab/5-Azacytidine in Acute Myeloid Leukemia (AML)TerminatedNCT02096042Phase 1/2Results posted
• MEK Inhibitor 162 Relapsed and/or Refractory Acute Myeloid Leukemia (AML) and Poor Prognosis, Not Suitable for or Unwilling to Receive Standard TherapyTerminatedNCT02089230Phase 1/2Results posted
• Eltrombopag With Decitabine in Advanced Myelodysplastic Syndrome (MDS)TerminatedNCT02010645Phase 2Results posted
• Lenalidomide as Immune Adjuvant in Patient's With Chronic Lymphocytic Leukemia (CLL)TerminatedNCT01924169Phase 2Results posted
• Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous LeukemiaCompletedNCT01904136Phase 1/2Results posted
• Study of Vosaroxin and Decitabine in Older Patients With Acute Myeloid Leukemia and High-risk Myelodysplastic SyndromeCompletedNCT01893320Phase 1/2Results posted
• Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid MalignanciesCompletedNCT01823198Phase 1/2Results posted
• Decitabine Followed by Clofarabine, Idarubicin, and Cytarabine in Acute LeukemiaCompletedNCT01794702Phase 1/2Results posted
• Decitabine for Older or Unfit Patients With Acute Myeloid Leukemia (AML)CompletedNCT01786343Phase 2Results posted
• Pilot Study to Determine Effects of the Btk Inhibitor PCI-32765 on Leukemia Cell Kinetics and Trafficking, Using Heavy Water Labeling in Subjects With CLL and SLLCompletedNCT01752426Phase 1/2Results posted
• E7070, Idarubicin and Cytarabine in Relapsed AML and High-Risk Myelodysplastic SyndromesCompletedNCT01692197Phase 2Results posted
• Erlotinib Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT01664897Phase 2Results posted
• Allogeneic Stem Cell Transplant for CLLTerminatedNCT01629511Phase 1/2Results posted
• Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine ConditioningCompletedNCT01572662Phase 2Results posted
• Ponatinib - Frontline for Chronic Myeloid Leukemia (CML) in Accelerated Phase (AP)TerminatedNCT01570868Phase 2Results posted
• Phase 2 Study of the Combination of Bruton's Tyrosine Kinase Inhibitor PCI-32765 and Rituximab in High-Risk Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma PatientsCompletedNCT01520519Phase 2Results posted
• An Open-Label, Phase I/II Study of Two Different Schedules of Dasatinib (Sprycel) and Decitabine (Dacogen) Used in Combination for Patients With Accelerated or Blastic Phase Chronic Myelogenous Leukemia (Protocol CA180357)TerminatedNCT01498445Phase 1/2Results posted
• Zevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT)CompletedNCT01490723Phase 2Results posted
• Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)CompletedNCT01471444Phase 3Results posted
• Ofatumumab as Front-Line Therapy in Treating Elderly Participants With Chronic Lymphocytic LeukemiaCompletedNCT01444716Phase 2Results posted
• Eltrombopag Olamine in Treating Thrombocytopenia in Patients With Chronic Myeloid Leukemia or Myelofibrosis Receiving Tyrosine Kinase TherapyCompletedNCT01428635Phase 2/3Results posted
• Pegasys in Patients With Chronic Myeloid Leukemia (CML)TerminatedNCT01392170Phase 2Results posted
• Alloreactive Haploidentical Natural Killer (NK) Cells With Busulfan and Fludarabine/ATGCompletedNCT01390402Phase 2Results posted
• Combination Chemotherapy and Ofatumumab in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic LymphomaCompletedNCT01363128Phase 2Results posted
• Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic LeukemiaCompletedNCT01319981Phase 2Results posted
• Clofarabine, Idarubicin, and Cytarabine (CIA) Versus Fludarabine, Idarubicin, and Cytarabine (FLAI) in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic SyndromeCompletedNCT01289457Phase 1/2Results posted
• Omacetaxine and Low Dose Cytarabine in Older Patients With Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)CompletedNCT01272245Phase 2Results posted
• Ofatumumab for Minimal Residual Disease (MRD) and Maintenance TherapyTerminatedNCT01258933Phase 2Results posted
• Sorafenib and 5-Azacitidine in Acute Leukemia + Myelodysplastic SyndromeCompletedNCT01254890Phase 1/2Results posted
• Sapacitabine, Cyclophosphamide, Rituximab for Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (CLL/SLL) With Deletion (11q22-23)TerminatedNCT01253460Phase 2Results posted
• Phase l/II Study of Ruxolitinib for Acute LeukemiaTerminatedNCT01251965Phase 1/2Results posted
• Ofatumumab for High-Risk Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)CompletedNCT01243190Phase 2Results posted
• Prophylactic White Cell Transfusions Versus Therapeutic White Cell Transfusions in Patients With LeukemiaTerminatedNCT01204788Phase 2Results posted
• PKC412 and 5-AzacytidineCompletedNCT01202877Phase 1/2Results posted
• Alemtuzumab in Myelodysplastic Syndrome (MDS), Aplastic Anemia, and T-Cell Large Granular Lymphocytic Leukemia (T-GL)TerminatedNCT01191749Phase 2Results posted
• Nuvigil in Treatment of Cancer-Related Fatigue in Chronic Myeloid Leukemia PatientsTerminatedNCT01169753Not applicableResults posted
• Phase II Eltrombopag in Chronic Lymphocytic Leukemia (CLL)CompletedNCT01168921Phase 2Results posted
• Plerixafor and Clofarabine in Frontline Treatment of Elderly Patients With Acute Myelogenous Leukemia (AML)TerminatedNCT01160354Phase 1/2Results posted
• Procrit Versus No Procrit in Acute Lymphocytic Leukemia, Lymphoblastic Lymphoma, or Burkitt's Undergoing Induction/Consolidation ChemotherapyCompletedNCT01099202Not applicableResults posted
• Fludarabine, Bendamustine, and Rituximab (FBR) for Relapsed Chronic Lymphocytic Leukemia (CLL)CompletedNCT01096992Phase 1/2Results posted
• Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)CompletedNCT01082939Phase 2Results posted
• 5-Azacytidine With Lenalidomide in Patients With High Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)CompletedNCT01038635Phase 1/2Results posted
• Clofarabine, Idarubicin, and Cytarabine Combination in Acute Myeloid Leukemia (AML) InductionCompletedNCT01025154Phase 2Results posted
• Fludarabine and Cytarabine in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)CompletedNCT01019317Phase 2Results posted
• Mismatched Transplantation Using High-dose Post-transplant CyclophosphamideCompletedNCT01010217Phase 2Results posted
• Lenalidomide and Ofatumumab in Treating Participants With Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaCompletedNCT01002755Phase 2Results posted
• Busulfan Plus Clofarabine Followed by Allogeneic Hematopoietic Stem Cell TransplantationCompletedNCT00990249Phase 2Results posted
• A Study for Leukemia Patients With Life-Threatening InfectionsCompletedNCT00968838Phase 3Results posted
• RAD001 Study in Treatment of Relapsed or Refractory Acute Lymphocytic LeukemiaCompletedNCT00968253Phase 1/2Results posted
• Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-risk Myelodysplastic SyndromeCompletedNCT00968071Phase 2Results posted
• Ondansetron Versus Aprepitant Plus Ondansetron for EmesisCompletedNCT00954941Phase 2Results posted
• Vorinostat in Combination With Azacitidine in Patients With Newly-Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)CompletedNCT00948064Phase 2Results posted